|

Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS

RECRUITINGN/ASponsored by Stony Brook University
Actively Recruiting
PhaseN/A
SponsorStony Brook University
Started2025-06-09
Est. completion2026-05-31
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07009691

Summary

The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are: Does the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve functioning in participants who have ME/CFS? Can HRV be used to predict who will benefit from treatment with hydrogen water?

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria: Meets Institute of Medicine criteria for myalgic encephalomyelitis/chronic fatigue syndrome -

Exclusion Criteria: Medical illness that explains presenting fatigue; Any psychosis.

\-

Conditions2

Chronic Fatigue SyndromeHeart Disease

Locations1 site

Stony Brook University
Stony Brook, New York, 11794-8101
Fred Friedberg, PhDfred.friedberg@stonybrookmedicine.edu

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.